Tirzepatide
- Evidence
- Approved drug evidence
- Class
- Dual GIP + GLP-1 receptor agonist
Tirzepatide belongs to the Dual GIP + GLP-1 receptor agonist class. This library groups it under digestive & weight. Its source category is FDA-approved.
At a glance
| Compound class | Dual GIP + GLP-1 receptor agonist |
|---|---|
| Associated brands | Mounjaro, Zepbound |
| Body system | Digestive & weight |
| Use or research focus | Type 2 diabetes; obesity; obstructive sleep apnea |
| Regulatory status | FDA-approved |
| Source evidence rating | Approved drug evidence |
How does Tirzepatide work?
Co-activates GIP and GLP-1 receptors for glycemic control and appetite suppression.
The source catalog maps this mechanism to Pancreas, Brain / CNS, Whole-body / Metabolic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
An approved medicine can still have contraindications, interactions, and serious adverse effects. The current prescribing label is the place to check product-specific warnings. A clinician should review your medical history and other medicines before treatment.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Tirzepatide?
Tirzepatide belongs to the Dual GIP + GLP-1 receptor agonist class. This library groups it under digestive & weight. Its source category is FDA-approved. Its recorded use or research focus is: Type 2 diabetes; obesity; obstructive sleep apnea.
Is Tirzepatide FDA-approved?
The catalog records: FDA-approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Where can I read the research?
The Citations tab contains 16 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for digestive & weight
Factual catalog fields and citation links are adapted from Superpower’s Tirzepatide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Tirzepatide in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01receptor agonistaccessdata.fda.gov
- 0220.9%doi.org
- 03Approvedaccessdata.fda.gov
- 04obstructive sleep apneafda.gov
- 05shown to reduce LDL cholesterol and triglyceridesdoi.org
- 06reduced HbA1c by 1.96 percentage pointsdoi.org
- 07regained 14.0%doi.org
- 08weight reductions of 12.8%doi.org
- 09Mounjaroaccessdata.fda.gov
- 10pediatric patients 10 years and olderaccessdata.fda.gov
- 11cardiovascular risk reductionaccessdata.fda.gov
- 12Zepboundaccessdata.fda.gov
- 13has not been evaluated by the FDAfda.gov
- 14reduced the apnea-hypopnea indexdoi.org
- 151.3% of tirzepatide-treated participantsdoi.org
- 16significantly higher odds of achieving ≥10% weight lossdoi.org